This Stealth Rally Is About to Explode into a Huge Bull Market

This Stealth Rally Is About to Explode into a Huge Bull Market
By Dr. George Huang
March 12, 2010

It was a "stealth" rally...

Over the first couple months of 2010, the U.S. stock market hovered around breakeven. Investors were too busy worrying about Greece's debt crisis, fourth-quarter earnings, and health care reform to notice what was happening over in my corner of the market.

While stocks in general crawled up about 2%, the benchmark Nasdaq Biotechnology Index staged an impressive double-digit rally. Take a look...

It was a huge jump. But almost nobody noticed... until early this month, when a new biotech bull market launched with fireworks and confetti.

On Monday March 1, Millipore, a laboratory supplier for the biotech industry, accepted a buyout offer from a German pharma conglomerate. The deal valued Millipore at $7.2 billion. That's more than four times revenue and a huge 15 times 2010 EBITDA (a 30% richer deal than I typically see in large-cap life-science takeovers).

On the same day, Japanese pharma Astellas made a $52-per-share cash offer to acquire OSI Pharmaceuticals, the biotech most famous for its lung cancer drug Tarceva. The deal values OSI at a 53% premium to its three-month average price and eight times sales. Incredibly, OSI's board swiftly rejected the bid as too low. Investors cheered, sending shares over $56.

The buyout fever continued this week, when health care conglomerate Abbott bought Facet Biotech, a pioneer in antibody technologies, for $27 per share – an astronomical 66% premium. Facet has no products on the market yet. But it has a potential blockbuster for multiple sclerosis in late-stage testing and a platform for discovering new antibody therapies.

These recent buyouts have woken investors to biotech's stealth bull market. This could be the start of something enormous... Previous biotech bull markets have netted average gains of 300%-500%.

Without industry expertise and years of practice, it's almost impossible to consistently pick individual winners out of the hundreds of publicly traded biotechs. A failed trial here or an FDA rejection there will wipe out your investment faster than a Vegas slot machine. Even a triple-digit uptrend in the sector won't protect you from a company-specific setback.

So for investors interested in grabbing a lot of the reward with a whole lot less risk, I think large, liquid exchange-traded funds are your best bet.

A Fatal Mistake for Biotech Traders

Make 50% from Billionaire Carl Icahn's Latest Target

The SPDR S&P Biotech ETF (XBI) offers the most diverse exposure to both large- and small-cap biotech names. The PowerShares Dynamic Biotech & Genome Portfolio (PBE) includes life-science equipment, service, and consumable players, as well as household biotech names. And the Biotech iShares (IBB), the most widely owned biotech ETF, tracks the Nasdaq biotech index with minimal expenses.

Personally, I like XBI best. The 25 biotechs in the index are all prime candidates on Big Pharma's takeout list. Owning this index assures that you'll profit from the buyout fever.

Good investing,

George Huang

Marc Faber: Don't short the euro now...
Wait until it hits this level.

If you're bullish on natural gas, you need to read this
"All in all, this doesn't bode well for natural gas – or its investors."

This trading ban could set off a new crisis
"The next 'Lehman-sized' event may be just around the corner."

•	Credit-card giant Visa hits fresh high... up 8.5% in March.
•	Home improvement superstores Lowe's and Home Depot at new highs.
•	Natural gas continues to tumble... futures slide 20% this year to new 2010 lows.
•	Earnings today... AnnTaylor, Kirkland's.

	Last	Change	52-Wk
S&P 500	1138.50	+0.00%	+66.60%
Oil (USO)	39.79	-0.15%	+42.16%
Gold (GLD)	109.88	-0.84%	+19.06%
Silver (SLV)	16.89	-0.71%	+28.15%
U.S. Dollar	80.78	+0.00%	-9.41%
Euro	1.36	+0.00%	+7.61%
VIX	17.79	+0.00%	-63.94%
HUI	424.20	-1.07%	+48.86%
10-Year Yield	3.71%	0.03	1.15

Advertisement

Company	Sym	Industry
Nike	NKE	athletic clothes
Starbucks	SBUX	coffee
Dr Pepper	DPS	soft drinks
Magellan Mid	MMP	pipelines
Visa	V	credit cards
eBay	EBAY	online auctions
Estee Lauder	EL	make-up
Cree	CREE	semiconductors
Valeant	VRX	pharma
Sony	SNE	electronics
Norfolk	NSC	railroads
Fifth Third	FITB	bank
Dolby Labs	DLB	electronics
BE Aerospace	BEAV	defense
Canon	CAJ	cameras
Enterprise Prod	EPD	oil & gas drilling
ConAgra	CAG	packaged foods
Ventas	VTR	health REIT
Amylin	AMLN	biotech
Union Pacific	UNP	railroads
Kinder Morgan	KMP	pipelines
Penn West	PWE	oil & gas drilling
Roper	ROP	industrial equip
CAE	CAE	defense
Lowe's	LOW	home goods
Baidu	BIDU	online search
Goodrich	GR	defense
Hasbro	HAS	toys
NovaGold	NG	gold
MetLife	MET	insurance
Home Depot	HD	home goods
Banco de Chile	BCH	bank
ONEOK	OKE	utilities

Company	Sym	Industry
Cbeyond	CBEY	telecom

A Simple Day-Trading Strategy
March 11, 2010

The Opportunity to Make Money Is Just Too Great to Pass Up
March 10, 2010

Another Commodity Set to Fall in Price
March 9, 2010

Why Professionals Aren't Buying This Rally
March 8, 2010

Weekend Edition: Four Recommended Reads from Porter Stansberry
March 6, 2010